Table 1Effects of Anti–TNF-α Biologic DMARDs on PsA Outcomes

The range of the effect sizes from individual studies (difference between drug and placebo) are shown.

Improvement in Disease ActivityFunctional Capacity (Mean Improvement)HRQoL (Mean Improvement)
Biologic DMARDsPercentage Achieving ACR20*HAQ; MCID0.22*SF-36 PCS; MCID = 2.2 to 4.7*
Adalimumab39 to 57 Image clinpafu2.jpg0.2 to 0.3 Image clinpafu2.jpg2.9 to 7.9 Image clinpafu3.jpg
Etanercept59 to 65 Image clinpafu2.jpg0.5 to 1.1 Image clinpafu2.jpg8.6 Image clinpafu3.jpg
Golimumab45 to 51 Image clinpafu3.jpg0.34 to 0.4 Image clinpafu3.jpg5.9 to 7.2 Image clinpafu3.jpg
Infliximab58 to 62 Image clinpafu2.jpg0.4 to 0.6 Image clinpafu2.jpg6.4 to 8 Image clinpafu3.jpg

The range of results from studies, from lowest to highest.

ACR20 = American College of Rheumatology 20-percent improvement from baseline to end point; DMARDs = disease-modifying anti-rheumatic drugs; HAQ = Health Assessment Questionnaire; HRQoL = health-related quality of life; MCID = minimum clinically important difference; PCS = physical component score; SF-36 = Medical Outcomes Study Short Form 36

From: Drug Therapy for Psoriatic Arthritis in Adults: Comparative Effectiveness

Cover of Comparative Effectiveness Review Summary Guides for Clinicians
Comparative Effectiveness Review Summary Guides for Clinicians [Internet].

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.